Neuropeptide Y and derivates are not ready for prime time in prostate cancer early detection
Neuropeptide Y (NPY) and related peptides have been proposed as promising biomarkers for the diagnosis of prostate cancer by previous immunoassays and immunohistochemical studies. In this study, we evaluated the additional value of NPY and related peptides compared with prostate-specific antigen (PS...
المؤلفون الرئيسيون: | Maurer, J, Eugster, PJ, Collins, K, Vocat, C, Oke, J, Nicholson, B, Rakauskas, A, Grouzmann, E, Valerio, M |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
Elsevier
2024
|
مواد مشابهة
-
Neuropeptide Y and Derivates Are Not Ready for Prime Time in Prostate Cancer Early Detection
حسب: Jonathan Maurer, وآخرون
منشور في: (2024-08-01) -
Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?
حسب: Alexander Meisel
منشور في: (2019-12-01) -
Saxagliptin: A potential doping agent? A randomized, double‐blinded, placebo‐controlled, and crossover pilot study in young active men
حسب: Nicolas Bourdillon, وآخرون
منشور في: (2022-12-01) -
Biomarkers in early-stage colorectal cancer: ready for prime time?
حسب: Church, D, وآخرون
منشور في: (2012) -
REBOA: is it ready for prime time?
حسب: Jay Doucet, وآخرون